I have long held the belief that digital therapeutics will be prescribed alongside drugs to improve patient outcomes, leading ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2024 investor ...

Experts in the neuropsychiatry drug development space say targeting the right patient population will be key for success in ...

Election Day is just about here, marking an end to the unpredictable ride that has been the 2024 presidential race following ...

The complexities of tech transfer may be overcome by data-driven approaches, digital tools, and effective communication.

This approach supports our long-term objective of establishing Bionoid Pharma as a leader in AI-powered health solutions." The AI-driven platform at the heart of BINP's growth strategy will ...

The study indicated that pharma ads can have a practical impact on disease awareness and the care journey for patients.

Joseph Stringer has given his Buy rating due to a combination of factors related to Inozyme Pharma’s financial and strategic positioning. The company’s announcement of their 3Q24 financial ...

Keay Nakae’s rating is based on several strategic and financial factors that position Alnylam Pharma favorably in the market. The company has demonstrated robust quarterly performance with a 34% ...

Zealand Pharma AS (ZLDPF) showcases promising trial results and strategic partnerships while navigating high R&D expenses and ...

Catalyx and INEL have announced a strategic partnership aimed at delivering comprehensive packaging solutions for the pharmaceutical sector. This collaboration is set to enhance processes such as ...

AI-Driven Platform and Strategic Acquisitions to Drive Health & Wellness Growth and Profitability TORONTO, ON / ACCESSWIRE / November 5, 2024 / Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP ...